- All
- Announcements
- News
- Publications & Posters
Announcements
6 December, 2021
Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets in cancer and autoimmune disease, and Cancer Research UK, the world’s leading cancer charity, today announced that the first patient has been dosed in a Phase 1 clinical trial of HMBD-001 for the treatment of patients with advanced HER3-expressing solid malignancies (NCT05057013).
Announcements
29 November, 2021
Hummingbird Bioscience Holdings Limited, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets in cancer and autoimmune disease, today announced the appointment of Jan Møller Mikkelsen as Chairman of its Board of Directors.
Announcements
10 November, 2021
Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced a Trials in Progress poster presentation outlining the Phase 1 clinical trial design for HMBD-002, a unique anti-VISTA antibody developed using Hummingbird’s Rational Antibody Discovery platform to address VISTA-mediated suppression of anti-tumor immune responses, at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). The meeting will be held in Washington, D.C. and virtually from November 10 to 14, 2021.
Announcements
25 October, 2021
Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets to improve treatment outcomes, today announced it has entered into a clinical trial collaboration agreement with Merck.
Announcements
7 October, 2021
Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced the presentation of pre-clinical data on novel biomarkers for HER3-driven cancers at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics 2021. The conference will take place from October 7 to 10, 2021.
Publications & Posters
7 October, 2021
Announcements
23 September, 2021
Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, has opened its new office location at the Singapore Science Park. The new base strengthens its Singapore presence and complements its offices in the United States at Texas Medical Centre and South San Francisco.
Announcements
13 September, 2021
Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced that the U.S. Food and Drug Administration (FDA) has approved the initiation of a Phase 1 clinical trial of HMBD-002, Hummingbird’s anti-VISTA neutralizing antibody.
Announcements
1 September, 2021
Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced the appointment of Josh House as Chief Financial Officer, effective immediately.
Announcements
2 August, 2021
Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the clinical trial application (CTA) to initiate first-in-human phase 1 trial of HMBD-001 in patients with advanced cancers.
Announcements
26 July, 2021
Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced that internationally renowned scientist and medical oncologist, Dr. Thomas J Lynch, Jr, MD, has been appointed to its Board as a Non-Executive Director, effective immediately.
Announcements
12 July, 2021
Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets to produce major improvements in treatment outcomes, and The University of Texas MD Anderson Cancer Center today announced the launch of a multi-year strategic research collaboration to investigate and evaluate HMBD-002, Hummingbird’s VISTA antagonist antibody.
Announcements
15 June, 2021
Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced that its Chief Scientific Officer and co-founder, Dr Jerome Boyd-Kirkup, will be speaking at the 2021 virtual symposium “VISTA: A New Immune Checkpoint in Cancer, Autoimmunity and Beyond”, taking place on June 18, 2021.
Announcements
9 June, 2021
Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced a strategic partnership with Asian genomic sequencing and bioinformatics company Novogene Co., Ltd. (“Novogene”).
Announcements
31 May, 2021
Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets today announced that its abstract reporting pre-clinical results from its V-domain immunoglobulin suppressor of T cell activation (VISTA) antibody, HMBD-002, has been selected for publication at the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held June 4-8, 2021.
News
27 May, 2021
Pharma Intelligence’s Insights speaks to Hummingbird CEO Piers Ingram following the Singapore-based company’s Series C financing round.
News
27 May, 2021
Hummingbird discusses our HER3 program and how we are tackling the challenges of therapeutics development.
News
27 May, 2021
Hummingbird discusses why cutting-edge digital tools and data-rich computational approaches play a powerful role in the development of precision biotherapeutics.
Announcements
18 May, 2021
Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets to improve treatment outcomes, today announced the close of its US$125 million Series C financing round.
Announcements
10 April, 2021
Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets to improve treatment outcomes, today announced that the company will be presenting pre-clinical data on its BCMA-TACI dual-specific T cell engager, HMBD-009, at the 2021 American Association for Cancer Research (AACR) Annual Meeting taking place 9-14 April.
Publications & Posters
10 April, 2021
News
24 February, 2021
Hummingbird discusses how systems biology and data science have advanced the understanding of disease, and how Hummingbird’s unique multidisciplinary approach unites the power of these two fields to create revolutionary therapies.
News
17 February, 2021
Hummingbird speaks to DealStreetAsia about Hummingbird’s overall drug development moving into clinical trials this year and why setting milestones drive future investments.
News
28 January, 2021
Hummingbird Bioscience has been recognized with the Most Promising Innovation title at Singapore’s SG:D Techblazer Awards 2020, the nation’s highest accolade for tech innovation.
News
12 January, 2021
The Business Times lists Hummingbird Bioscience as one of the Top 10 Startups to watch in Singapore in 2021.